by Leandra BernsteinFriday, January 29th 2021AA
11VIEW ALL PHOTOSFILE – In this Jan. 15, 2021, file photo, Dr. Yomaris Pena, Internal Medicine Physician with Somos Community Care at a COVID-19 extracts the last bit of Pfizer-BioNTech COVID-19 Vaccine out of a vial so as not to waste it at a vaccination site at the Corsi Houses in the East Harlem neighborhood of New York. (AP Photo/Mary Altaffer, File)
WASHINGTON (Sinclair Broadcast Group) —Concerns about the emergence of more infectious strains of thecoronavirusovershadowed the good news from Johnson & Johnson that it had completed the third phase clinical trial of its single-dose vaccine.
On Friday, Johnson & Johnson and Janssen Pharmaceuticals reported their vaccine was 72% effective among trial participants in the United States. But that efficacy went down to 57% in a South Africa trial, where the dominant strain of the virus is more transmissible and apparently…
View original post 1,079 more words
Exposing the Big Game 